Strata Skin Sciences

SSKN · NASDAQ

$0.00+$0.0001 (−100.00%)TodayMarket closed ·
No price history for this range.

Key indicators

SSKN profitability and balance sheet ratios

EPS $0.01 in Q4 FY25, against -$1.08 a year earlier.

EPS by quarter
PeriodEPS
Q1 FY24-$0.9606
Q2 FY24-$0.0282
Q3 FY24-$0.5254
Q4 FY24-$1.08
Q1 FY25-$0.5831
Q2 FY25-$0.5967
Q3 FY25-$0.3619
Q4 FY25$0.01

Where the money went

Q4 FY25, from revenue to net income

Strata Skin Sciences brought in $9.3M of revenue in Q4 FY25, −3.0% on a year earlier. 1¢ of every dollar became profit.

Revenue
$9.3M
Costs, expenses and taxes
$9.2M
Net income
$0.1M
Net margin
0.6%

Income statement

Revenue and profit by reporting period

Revenue
Net income
SSKN income statement, quarterly
Line itemQ2 FY25Q3 FY25Q4 FY25
Revenue$7.7M$6.9M$9.3M
Gross profit$4.3M$4.2M$5.6M
Operating income−$2.2M−$1.9M$1.2M
Net income−$2.5M−$1.6M$0.1M
Diluted EPS-$0.60-$0.36$0.01

Balance sheet

What the company owns and owes at period end

Total assets
Total liabilities
SSKN balance sheet, quarterly
Line itemJun 2025Sep 2025Dec 2025
Total assets$30.7M$30.7M$30.5M
Total liabilities$30.4M$29.4M$27.6M
Shareholder equity$0.3M$1.3M$2.9M
Cash and short-term investments$6.0M$7.1M$7.9M
Total debt$15.3M$15.3M$15.3M

Cash flow

Cash in and out from operations, investing and financing

Operating
Investing
Financing
SSKN cash flow, quarterly
Line itemQ2 FY25Q3 FY25Q4 FY25
Operating cash flow−$1.9M−$0.1M−$0.2M
Investing cash flow$0.1M−$1.0M−$0.3M
Financing cash flow$0.0M$2.2M$1.4M
Capital expenditure−$0.1M−$1.0M−$0.3M
Free cash flow−$2.0M−$1.1M−$0.6M

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.